Leerink Partnrs Issues Negative Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($1.35) for the quarter, down from their previous estimate of ($1.25). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics' Q2 2025 earnings at ($1.38) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.45) EPS, FY2025 earnings at ($5.58) EPS and FY2026 earnings at ($5.50) EPS.

A number of other equities analysts have also recently commented on the stock. Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, January 7th. Truist Financial raised their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, February 12th. JMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Barclays boosted their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Finally, Chardan Capital decreased their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating for the company in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $73.11.

CRISPR Therapeutics Trading Up 0.6 %

Shares of NASDAQ CRSP traded up $0.23 during mid-day trading on Friday, reaching $39.46. The company had a trading volume of 1,068,794 shares, compared to its average volume of 1,632,443. CRISPR Therapeutics has a 52-week low of $30.04 and a 52-week high of $67.88. The stock has a market cap of $3.41 billion, a P/E ratio of -9.03 and a beta of 1.85. The firm has a 50 day simple moving average of $40.74 and a two-hundred day simple moving average of $43.65.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Insider Activity

In other news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the sale, the general counsel now owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares in the company, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,381 shares of company stock valued at $1,608,243 over the last 90 days. Insiders own 4.10% of the company's stock.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently made changes to their positions in CRSP. Wood Tarver Financial Group LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $30,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Ameriflex Group Inc. bought a new stake in CRISPR Therapeutics in the fourth quarter valued at $36,000. Highline Wealth Partners LLC bought a new position in CRISPR Therapeutics in the 4th quarter worth about $39,000. Finally, Western Pacific Wealth Management LP increased its position in CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock valued at $39,000 after acquiring an additional 500 shares during the period. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.